Neos Therapeutics Inc. (NASDAQ:NEOS)‘s stock had its “buy” rating reiterated by equities researchers at BMO Capital Markets in a research report issued to clients and investors on Friday.

Separately, Zacks Investment Research cut Neos Therapeutics from a “hold” rating to a “sell” rating in a report on Wednesday, October 12th. One investment analyst has rated the stock with a hold rating and four have assigned a buy rating to the stock. Neos Therapeutics currently has a consensus rating of “Buy” and a consensus price target of $20.94.

Shares of Neos Therapeutics (NASDAQ:NEOS) opened at 8.35 on Friday. The company’s market capitalization is $134.18 million. Neos Therapeutics has a 1-year low of $5.30 and a 1-year high of $16.46. The stock has a 50 day moving average price of $6.48 and a 200 day moving average price of $8.02.

In other news, CFO Richard I. Eisenstadt acquired 3,710 shares of the business’s stock in a transaction on Thursday, August 25th. The stock was bought at an average cost of $6.82 per share, for a total transaction of $25,302.20. Following the purchase, the chief financial officer now owns 3,710 shares in the company, valued at $25,302.20. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Company insiders own 4.85% of the company’s stock.

Large investors have recently bought and sold shares of the company. Bank of New York Mellon Corp raised its stake in Neos Therapeutics by 73.1% in the second quarter. Bank of New York Mellon Corp now owns 38,008 shares of the company’s stock valued at $353,000 after buying an additional 16,046 shares during the period. California State Teachers Retirement System raised its stake in Neos Therapeutics by 140.1% in the second quarter. California State Teachers Retirement System now owns 28,815 shares of the company’s stock valued at $267,000 after buying an additional 16,815 shares during the period. Vanguard Group Inc. raised its stake in Neos Therapeutics by 12.3% in the second quarter. Vanguard Group Inc. now owns 293,989 shares of the company’s stock valued at $2,729,000 after buying an additional 32,266 shares during the period. BlackRock Investment Management LLC raised its stake in Neos Therapeutics by 151.0% in the second quarter. BlackRock Investment Management LLC now owns 51,386 shares of the company’s stock valued at $477,000 after buying an additional 30,915 shares during the period. Finally, BlackRock Fund Advisors raised its stake in Neos Therapeutics by 58.5% in the second quarter. BlackRock Fund Advisors now owns 566,112 shares of the company’s stock valued at $5,254,000 after buying an additional 209,054 shares during the period. Institutional investors own 38.59% of the company’s stock.

About Neos Therapeutics

Neos Therapeutics, Inc is a pharmaceutical company. The Company is focused on developing, manufacturing and commercializing products utilizing its modified-release drug delivery technology platform. Its segment is engaged in the development, manufacturing and commercialization of pharmaceuticals. It has utilized its platform to develop its product for the treatment of attention deficit hyperactivity disorder (ADHD).

5 Day Chart for NASDAQ:NEOS

Receive News & Stock Ratings for Neos Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neos Therapeutics Inc. and related stocks with our FREE daily email newsletter.